MARKET

NMRD

NMRD

Nemaura Medical Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.830
0.000
0.00%
Closed 16:00 12/03 EST
OPEN
3.800
PREV CLOSE
3.830
HIGH
4.050
LOW
3.700
VOLUME
31.06K
TURNOVER
--
52 WEEK HIGH
16.50
52 WEEK LOW
2.500
MARKET CAP
87.74M
P/E (TTM)
-18.2904
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Nemaura Medical Launches BEAT(TM)diabetes Program Through New Web Presence and Re-Launches Enhanced Corporate Website
Nemaura Medical, Inc. (NASDAQ: NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the re-launch of its corporate website, www.nemauramedical.com, and the website for its flagship program, BEAT(TM)diabetes, www.beatdiabetes.life, which serves as the unofficial launch of the program and allows users to register and learn about participating in an overall health management system to potentially reverse Type 2 diabetes.
GlobeNewswire · 11/17 13:30
Nemaura Medical Launches BEATdiabetes Program Through New Web Presence and Re-Launches Enhanced Corporate Website
LOUGHBOROUGH, England, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the re-launch of its corporate website, www.nemauramedical.com, and the website for its flagship program, BEAT™diabetes, www.beatdiabetes.life, which serves as the unofficial launch of the program and allows users to register and learn about participating in an overall health management system to potentially reverse Type 2 diabetes.“The launch of the BEAT™diabetes program website is an important entry into the market to allow consumers to access many of the life management tools that come with the program. In addition to introducing the smartphone and tablet app, which will provide users with our scientifically validated, personalized coaching driven by our digital platform, it also provides users with a portal to become among the first to access our non-invasive glucose monitor, which we expect to launch shortly. We believe that the combined use of the app with our sugarBEAT® monitor, has the potential to help reduce diabetes risk and even potentially reverse Type 2 diabetes with continued and dedicated use. We welcome all visitors to register for the BEAT™diabetes program and to experience the benefits of our coaching and monitoring programs to improve their overall health,” commented Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer.“In addition, the re-launch of our corporate website provides visitors with a more comprehensive view of our company. Previously, many visitors had equated one of our single products with the company in general. However, Nemaura is constantly developing its technology and already has designed multiple products that are in the process of being refined for regulatory approval and launch. This new website will give consumers and investors alike a better view of Nemaura and what we have to offer,” concluded Dr. Chowdhury.About Nemaura Medical, Inc.Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and is expected to be launched in the U.S. as a general wellness product.  The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.For more information, please visit www.NemauraMedical.com.Cautionary Statement Regarding Forward-Looking Statements:The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.Contact:Jules Abraham CORE IR 917-885-7378 julesa@coreir.com
GlobeNewswire · 11/17 13:00
Nemaura Medical Says Plans To Launch proBEAT Non-Invasive Wearable Glucose Monitor In Dec. 2020
Nemaura Medical Reports Financial Results for Second Quarter of Fiscal Year 2020/21 and Provides Corporate Update LOUGHBOROUGH, England, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.
Benzinga · 11/16 13:07
Nemaura Medical Q2 EPS $(0.07) Down From $(0.05) YoY
Nemaura Medical (NASDAQ:NMRD) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year.
Benzinga · 11/16 13:06
Nemaura Medical Reports Financial Results for Second Quarter of Fiscal Year 2020/21 and Provides Corporate Update
Nemaura Medical, Inc. (NASDAQ: NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces financial results for the second quarter ended September 30, 2020 and provides a corporate update.
GlobeNewswire · 11/16 13:00
Nemaura Medical Reports Financial Results for Second Quarter of Fiscal Year 2020/21 and Provides Corporate Update
LOUGHBOROUGH, England, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized  lifestyle coaching programs, today announces financial results for the second quarter ended September 30, 2020 and provides a corporate update. Recent and Second Quarter Highlights include: * In-licensed global rights to Healthimation, LLC’s mobile application based digital program, a well-validated and award-winning 12-week program to help patients manage their weight as part of a diabetes prevention or management program. The program is intended to be combined with the Company’s proBEAT™ non-invasive Glucose monitoring patch, with the aim of empowering users with knowledge of factors that could affect their blood glucose levels. * Appointed Justin McLarney as the Company’s Chief Financial Officer * Commissioned the integration of data from third-party wearable devices into the proBEAT™ app.  * Submitted the PMA application for sugarBEAT® to the United States Food and Drug Administration (FDA) * Completed $11.5M public offering ($10.7M after associated costs) * Terminated ATM with Maxim“The second quarter has been pivotal to our Company, as we have laid the groundwork for product launch of sugarBEAT® in the UK and Europe, and a diabetes management and reversal program in the USA,” commented Faz Chowdhury, Nemaura’s CEO.  “We continue to carefully manage our finances as we plan for a multinational launch and believe that we are at the forefront of changing the way consumers approach managing and preventing diabetes.”In December 2020 in the U.S., Nemaura plans to launch proBEAT™, a non-invasive, wearable glucose monitor that will gather data on factors affecting blood glucose profiles, combined with a behavioral change and weight management digital app that was developed by Healthimation Inc. that may help diabetic and pre-diabetic patients better manage, reverse, or prevent the onset of diabetes.  In the U.S., there are currently 88 million patients considered to be pre-diabetic and 25 million patients with Type 2 diabetes.  Worldwide, there are 420 million patients with diabetes and over 1 billion people considered pre-diabetic.Second Quarter 2020 Financial ResultsNet loss for the second quarter of 2020 was $1,581,217 as compared to $1,117,040 during the same period of 2019. Research and development expenses were $456,280 and $462,517 for the three-month periods ended September 30, 2020 and 2019, respectively.  This continues to be largely composed of expenditure on wages and sub-contractor activities incurred in finalizing the product design for the sugarBEATTM device in order to enable scaling of production capacity. General and administrative expenses were $771,533 and $654,523 for the three-month periods ended September 30, 2020 and 2019, respectively.  Given the nature of the Company’s activities has remained unchanged, the cost drivers in this area have also remained consistent and are largely representative of fees for legal, professional, consultancy, audit services, investor relations, insurance, and wages.The Company also incurred a charge of $353,404 for the three-month period ended September 30, 2020 on account of the accretion of debt discount in relation to the Secured Loan Note that the Company entered into in April 2020. Cash as of September 30, 2020 was $16,948,939. About Nemaura Medical, Inc.Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.  The company is currently commercializing sugarBEAT® and proBEAT™.  sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes.  Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA.  proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and is expected to be launched in the U.S. as a general wellness product. The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.For more information, please visit www.NemauraMedical.com.Cautionary Statement Regarding Forward-Looking Statements:The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.  Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®.  There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product.  These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.  Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.Contact:Jules Abraham CORE IR 917-885-7378 julesa@coreir.com NEMAURA MEDICAL INC. Condensed Consolidated Balance Sheets  As of September 30, 2020 ($)As of March 31, 2020 ($)  (Unaudited)  ASSETS   Current assets:   Cash16,948,939 106,107  Prepaid expenses and other receivables358,404 452,463  Inventory (raw materials)411,620 286,309  Total current assets17,718,963 844,879      Other assets:   Property and equipment, net of accumulated depreciation152,893 162,064  Intangible assets, net of accumulated amortization237,150 213,080  Total other assets390,043 375,144  Total assets18,109,006 1,220,023      LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)   Current liabilities:   Accounts payable155,609 293,608  Liability due to related parties153,533 830,093  Other liabilities and accrued expenses47,609 168,966  Notes payable, net of unamortized discount2,431,913 -  Deferred revenue96,930 93,022  Total current liabilities2,885,594 1,385,689      Non-current portion of notes payable, net of unamortized discount2,785,515 -  Non-current portion of deferred revenue1,195,470 1,147,278  Total non-current liabilities3,980,985 1,147,278  Total liabilities6,866,579 2,532,967      Commitments and contingencies:       Stockholders’ equity (deficit):   Series A convertible preferred stock, $0.001 par value, 200,000 shares authorized; 0 shares issued and outstanding at September 30, 2020 and March 31, 2020- -  Common stock, $0.001 par value,   42,000,000 shares authorized and 22,893,705 and 20,850,848   shares issued and outstanding at September 30, 2020 and March 31, 2020, respectively22,894 20,851  Additional paid-in capital31,838,383 16,589,272  Accumulated deficit(20,267,348)(17,586,075) Accumulated other comprehensive loss(351,502)(336,992) Total stockholders’ equity/ (deficit)11,242,427 (1,312,944) Total liabilities and stockholders’ equity18,109,006 1,220,023  See notes to the unaudited condensed consolidated financial statements.   NEMAURA MEDICAL INC. Condensed Consolidated Statements of Comprehensive Loss (Unaudited)  Three Months Ended September 30,Six Months Ended September 30,  2020 ($)2019 ($)2020 ($)2019 ($)       Revenue:- - - -  Total revenue- - - -        Operating expenses:     Research and development456,280 462,517 771,592 1,018,699  General and administrative771,533 654,523 1,367,253 1,353,532  Total operating expenses1,227,813 1,117,040 2,138,845 2,372,231        Loss from operations(1,227,813)(1,117,040)(2,138,845)(2,372,231)       Interest (expense) income(353,404)- (542,428)3,926  Net loss(1,581,217)(1,117,040)(2,681,273)(2,368,305)       Other comprehensive loss:     Foreign currency translation adjustment(19,334)(7,401)(14,510)(23,152) Comprehensive loss(1,600,551)(1,124,441)(2,695,784)(2,391,457)       Loss per share:     Basic and diluted(0.07)(0.05)(0.12)(0.11) Weighted average number of shares outstanding22,384,986 20,802,197 21,636,330 20,792,967  See notes to the unaudited condensed consolidated financial statements. NEMAURA MEDICAL INC. Condensed Consolidated Statements of Changes in Stockholders’ Equity Three Months Ended September 30, 2020 and 2019 (Unaudited) Common Stock          Shares Amount  Additional Paid-in Capital  Accumulated Deficit  Accumulated Other Comprehensive Loss  Total Stockholders’ Equity    ($) ($) ($) ($) ($) Balance at June 30, 202021,282,133 21,282 20,957,486 (18,686,131) (332,169) 1,960,468  Issuance of common shares under ATM financing, net of offering costs of $845,0301,611,572 1,612 10,880,897 -  -  10,882,509  Foreign currency translation adjustment - - - -  (19,334) (19,334) Net loss- - - (1,581,217) -  (1.581,217) Balance at September 30, 202022,893,705 22,894 31,838,383 (20,267,348) (351,502) 11,242,427               Balance at June 30, 201920,801,680 20,802 16,320,359 (14,677,144) (355,639) 1,308,378  Restricted shares issued as stock-based compensation to consultants and investor relations1,250 1 12,375 -  -  12,376  Foreign currency translation adjustment- - - -  (7,401) (7,401) Net loss- - - (1,117,040) -  (1,117,040) Balance at September 30, 201920,802,930 20,803 16,332,734 (15,794,184) (363,040) 196,313  See notes to the unaudited condensed consolidated financial statements. NEMAURA MEDICAL INC. Condensed Consolidated Statements of Changes in Stockholders’ Equity Six Months Ended September 30, 2020 and 2019 (Unaudited) Common Stock          Shares Amount  Additional Paid-in Capital  Accumulated Deficit  Accumulated Other Comprehensive Loss  Total Stockholders’ Equity    ($) ($) ($) ($) ($) Balance at March 31 202020,850,848 20,851 16,589,272 (17,586,075) (336,992) (1,312,944) Issuance of common shares under ATM financing, net of offering costs of $967,9432,004,924 2,005 14,854,674 -  -  14,856,679  Exercise of warrants 37,933 38 394,437 -  -  394,475  Foreign currency translation adjustment- - - -  (14,510) (14,510) Net loss- - - (2,681,273) -  (2,681,273) Balance at September 30, 202022,893,705 22,894 31,838,383 (20,267,348) (351,502) 11,242,427               Balance at March 31, 201920,765,592 20,766 15,971,905 (13,425,879) (339,888) 2,226,904  Exercise of warrants 2,500 2 25,998 -  -  26,000  Issuance of common shares under ATM financing, net of offering costs of $9,57514,338 14 142,903 -  -  142,917  Restricted shares issued as stock- based compensation to consultants and investor relations20,500 21 191,928 -  -  191,949  Foreign currency translation adjustment- - - -  (23,152) (23,152) Net loss- - - (2,368,305) -  (2,368,305) Balance at September 30, 201920,802,930 20,803 16,332,734 (15,794,184) (363,040) 196,313  See notes to the unaudited condensed consolidated financial statements.   NEMAURA MEDICAL INC. Condensed Consolidated Statements of Cash Flows (Unaudited)  Six Months Ended September 30,  2020 ($)2019 ($)     Cash Flows From Operating Activities:   Net loss(2,681,273)(2,368,305)     Adjustments to reconcile net loss to net cash used in operating activities:   Depreciation and amortization40,746 28,338  Accretion of debt discount542,428 -  Stock-based compensation59,000 277,664  Changes in assets and liabilities:   Prepaid expenses and other receivables94,059 263,022  Inventory(125,311)(170,371) Accounts payable(137,999)59,010  Liability due to related parties(676,560)100,533  Other liabilities and accrued expenses(121,357)(52,608) Net cash used in operating activities(3,006,267)(1,862,717)     Cash Flows from Investing Activities:   Capitalized patent costs(27,600)(28,310) Purchase of property and equipment(14,032)(133,716) Net cash used in investing activities(41,632)(162,026)     Cash Flows from Financing Activities:   Costs incurred in relation to ATM equity financing(957,193)(9,575) Commission paid on note payable(325,000)-  Proceeds from issuance of notes5,000,000 -  Proceeds from issuance of common stock in relation to ATM financing15,750,672 152,492  Proceeds from warrant exercise394,475 26,000  Repayments of note payable(82,555)-  Net cash provided by financing activities19,780,399 168,917      Net increase (decrease) in cash16,732,500 (1,855,826) Effect of exchange rate changes on cash110,332 (113,723) Cash at beginning of period106,107 3,740,664  Cash at end of period16,948,939 1,771,115      Supplemental disclosure of non-cash financing activities:   Prepayment of equity compensation- 85,715  See notes to the unaudited condensed consolidated financial statements.
GlobeNewswire · 11/16 13:00
Nemaura Medical to Present at Virtual Diabetes Technology Meeting 2020
Nemaura Medical, Inc. (NASDAQ: NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it will present on Day 1 of the Virtual Diabetes Technology Meeting 2020 on November 12, 2020 at 2:50 PT. Nemaura's Chief Executive Officer Dr. Faz Chowdhury will give a presentation titled "CGM Usage for the Management and Reversal of Type 2 diabetes."
GlobeNewswire · 10/22 12:00
Nemaura Medical to Present at Virtual Diabetes Technology Meeting 2020
LOUGHBOROUGH, England, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it will present on Day 1 of the Virtual Diabetes Technology Meeting 2020 on November 12, 2020 at 2:50 PT. Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will give a presentation titled “CGM Usage for the Management and Reversal of Type 2 diabetes.” Due to the impact of COVID-19, the 20th Annual Diabetes Technology Meeting will be held as a virtual event. The meeting’s goal is to connect technology developers and users to facilitate the creation of new and cost-effective tools to help people with diabetes. FDA officials also participate in the meeting and will update attendees on current U.S. regulatory policies. The sharing of original data is particularly emphasized, too.   The format of the meeting will include state-of-the-art lectures, oral presentations of abstracts, panel discussions with Q & A sessions, and virtual poster sessions. Investors wishing to view Dr. Chowdhury’s presentation can register for the meeting at https://www.diabetestechnology.org/dtm/.In December 2020 in the U.S., Nemaura plans to launch proBEAT™, a non-invasive, wearable, glucose monitor which is expected to help users improve their knowledge of how a range of lifestyle, dietary and health and wellbeing factors impact their sugar levels by acting like a black box flight recorder. Big data about the multitude of factors that affect glucose levels will be gathered and used to provide artificial intelligence based feedback and prompts.  This will be combined with a behavioral change and weight management digital app in-licensed from Healthimation Inc. and is expected to collectively help diabetic and pre-diabetic patients better manage, reverse, or prevent the onset of diabetes.   In the U.S., there are currently 88 million patients considered to be pre-diabetic and 25 million patients with Type 2 diabetes. Worldwide, there are 420 million patients with diabetes and over 1 billion people considered pre-diabetic. About Nemaura Medical, Inc.Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and is expected to be launched in the U.S. as a general wellness product.  The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.For more information, please visit www.NemauraMedical.com.Cautionary Statement Regarding Forward-Looking Statements:The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.Contact:Jules Abraham CORE IR 917-885-7378 julesa@coreir.com
GlobeNewswire · 10/22 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NMRD. Analyze the recent business situations of Nemaura Medical Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NMRD stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 1.52M
% Owned: 6.63%
Shares Outstanding: 22.91M
TypeInstitutionsShares
Increased
8
29.89K
New
9
704.75K
Decreased
7
35.90K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.54%
Healthcare Equipment & Supplies
-0.35%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dewan Chowdhury
Chief Financial Officer
Justin Mclarney
Vice President
Chris Avery
Director
Bashir Timol
Independent Director
Timothy Johnson
Independent Director
Thomas Moore
Independent Director
Salim Natha
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NMRD
Nemaura Medical, Inc. is a holding company. The Company, through its subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients. SugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five-minute intervals via a mobile app. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s subsidiaries include Region Green Limited.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Nemaura Medical Inc stock information, including NASDAQ:NMRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMRD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NMRD stock methods without spending real money on the virtual paper trading platform.